10-11-2013

Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral Therapy

D Moyo
G Tanthuma
O Mushisha
G Kwadiba
F Chikuse

See next page for additional authors

Follow this and additional works at: http://repository.upenn.edu/botswana_schol

Part of the Endocrinology, Diabetes, and Metabolism Commons, and the Immune System Diseases Commons

Recommended Citation
Moyo, D; Tanthuma, G; Mushisha, O; Kwadiba, G; Chikuse, F; Cary, Mark S.; Steenhoff, Andrew P.; and Reid, Michael J. A, "Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral Therapy" (2013). Botswana-UPenn Scholarly Publications. Paper 5.
http://repository.upenn.edu/botswana_schol/5

This paper is posted at ScholarlyCommons. http://repository.upenn.edu/botswana_schol/5
For more information, please contact repository@pobox.upenn.edu.
Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral Therapy

Abstract

Background. There is little in the literature on HIV and diabetes mellitus (DM) in sub-Saharan Africa.

Objective. To assess the characteristics of HIV and DM in patients receiving antiretroviral therapy (ART) in Botswana.

Methods. A retrospective case-control study was conducted at 4 sites. Each HIV-infected patient with DM ($n=48$) was matched with 2 HIV-infected controls ($n=108$) by age (±2 years) and sex. Primary analysis was conditional logistic regression to estimate univariate odds and 95% confidence intervals (CIs) for each characteristic.

Results. There was no significant association between co-morbid diseases, tuberculosis, hypertension or cancer and risk of diabetes. DM patients were more likely to have higher pre-ART weight (odds ratio (OR) 1.09; 95% CI 1.04 - 1.14). HIV-infected adults >70 kg were significantly more likely to have DM (OR 12.30; 95% CI 1.40 - 107.98). Participants receiving efavirenz (OR 4.58; 95% CI 1.44 - 14.57) or protease inhibitor therapy (OR 20.7; 95% CI 1.79 - 240.02) were more likely to have DM. Neither mean pre-ART CD4 cell count (OR 1.0; 95% CI 0.99 - 1.01) nor pre-ART viral load >100 000 copies/ml (OR 0.71; 95% CI 0.21 - 2.43) were associated with a significant risk of diabetes.

Conclusions. These findings suggest a complex interrelation among traditional host factors and treatment-related metabolic changes in the pathogenesis of DM inpatients receiving ART. Notably, pre-ART weight, particularly if >70 kg, is associated with the diagnosis of diabetes in HIV-infected patients in Botswana.

Keywords
diabetes mellitus, risk factors, HIV, metabolic co-morbidities, sub-Saharan Africa

Disciplines
Endocrinology, Diabetes, and Metabolism | Immune System Diseases

Author(s)
D Moyo, G Tanthuma, O Mushisha, G Kwadiba, F Chikuse, Mark S. Cary, Andrew P. Steenhoff, and Michael J. A Reid

This journal article is available at ScholarlyCommons: http://repository.upenn.edu/botswana_schol/5
Diabetes mellitus in HIV-infected patients receiving antiretroviral therapy

D Moyo, BPharm (Hons), PGDPH; G Tanthuma, BSc, PGDE, MA; O Mushisha, BPharm (Hons); G Kwadiba, PharmD; F Chikuse, HBMLS; M S Cary, PhD; A P Steenhoff, MB BCH, DCH (UK), FCPaed (SA), FAAP; M J A Reid, MD, MA, MRCP (UK)

1 Institute for Health Sciences, Gaborone, Botswana
2 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, USA
3 Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
4 Botswana/UPenn Partnership, Gaborone, Botswana
5 Center for AIDS Research, University of Pennsylvania, Philadelphia, USA
6 Department of Pediatrics, Division of Infectious Diseases, The Children’s Hospital of Philadelphia, USA
7 School of Medicine, University of Botswana, Gaborone, Botswana

Corresponding author: M J A Reid (michael.j.a.reid@gmail.com)

Background. There is little in the literature on HIV and diabetes mellitus (DM) in sub-Saharan Africa. To assess the characteristics of HIV and DM in patients receiving antiretroviral therapy (ART) in Botswana.

Objective. To assess the characteristics of HIV and diabetes mellitus (DM) in patients receiving antiretroviral therapy (ART) in Botswana.

Methods. A retrospective case-control study was conducted at 4 sites. Each HIV-infected patient with DM (n=48) was matched with 2 HIV-infected controls (n=108) by age (±2 years) and sex. Primary analysis was conditional logistic regression to estimate univariate odds and 95% confidence intervals (CIs) for each characteristic.

Results. There was no significant association between co-morbid diseases, tuberculosis, hypertension or cancer and risk of diabetes. DM patients were more likely to have higher pre-ART weight (odds ratio (OR) 1.09; 95% CI 1.04 - 1.14). HIV-infected adults >70 kg were significantly more likely to have DM (OR 12.30; 95% CI 1.40 - 107.98). Participants receiving efavirenz (OR 4.58; 95% CI 1.44 - 14.57) or protease inhibitor therapy (OR 20.7; 95% CI 1.79 - 240.02) were more likely to have DM. Neither mean pre-ART CD4 cell count (OR 1.0; 95% CI 0.99 - 1.01) nor pre-ART viral load >100 000 copies/ml (OR 0.71; 95% CI 0.21 - 2.43) were associated with a significant risk of diabetes.

Conclusions. These findings suggest a complex interrelation among traditional host factors and treatment-related metabolic changes in the pathogenesis of DM inpatients receiving ART. Notably, pre-ART weight, particularly if >70 kg, is associated with the diagnosis of diabetes in HIV-infected patients in Botswana.
groups: <40, 40 - 49, and ≥50 years). Statistical analyses were performed using STATA software version 12. All tests of significance were 2-sided with p ≤ 0.05 designated as statistically significant.

This study was approved by the Institutional Review Boards of Princess Marina and Nyangabgwe Referral Hospitals and the Botswana Ministry of Health.

Results
In total, there were 48 cases (28 females, 20 males, age mean 46.4 years ± standard deviation (SD) 9.9) and 108 controls (57 females, 51 males, age mean ±SD 43.6 ± 8 years) who had initiated ART between January 2001 and February 2011. Data were available on prescribed anti-diabetic medications in the majority of cases (n=28): 21% (n=6) were receiving metformin, 60% (n=17) receiving metformin and glimepiride and 18% (n=5) receiving an insulin-based regimen. Cases were matched with 108 HIV-infected control patients without DM. Table 1 summarises the baseline characteristics of both cohorts.

There was no significant association between the risk of having DM and either hypertension, active tuberculosis, cancer or reported adherence of <95%. However, undocumented adherence to ART was associated with an increased diabetes risk.

Weight at initiation of ART was statistically significant. In this case-control study, there were several notable findings. Firstly, diabetic patients with HIV had higher baseline weight compared with non-diabetics. Individuals with pre-ART weights of >70 kg had significantly higher risk of having diabetes, compared with those with baseline weights of <50 kg. This finding is consistent with established data that insulin resistance correlates with increased weight gain and obesity.[5] However, it is an important finding in this population since initiation of ART is itself associated with rapid weight gain.[21] Furthermore, the importance of targeted risk reduction strategies for overweight and obese individuals starting ART is highlighted.

Discussion
In this case-control study, there were several notable findings. Firstly, diabetic patients with HIV had higher baseline weight compared with non-diabetics. Individuals with pre-ART weights of >70 kg had significantly higher risk of having diabetes.
Secondly, there were associations between both EFV and PI exposures and DM. While there is substantial literature indicating that ART plays a causative or permissive role in the pathogenesis of DM in HIV-infected patients, most research has demonstrated a link between DM and thymidine analogues[3] and PI therapy.[3,11] Our finding that EFV was associated with diabetes is especially notable given that EFV is part of first-line ART regimens across SSA because of its perceived lower toxicity compared with nevirapine. Researchers in Cape Town, South Africa found that EFV was significantly associated with impaired glucose tolerance even after controlling for body mass index and waist circumference.[3,11] Participants in that study had all been receiving EFV for at least 6 months at the time of enrolment, suggesting that EFV may accelerate insulin resistance. We speculate that the effect of EFV in our analysis was mediated by weight – those with a priori obesity receiving EFV were more likely to have DM. Unfortunately, our sample size was not large enough to prove conclusively that this was the case. More prospective research is needed to elucidate how EFV influences diabetogenesis, especially in individuals with pre-ART weights >70 kg.

Thirdly, our analysis failed to demonstrate an association between HIV-specific factors and DM. Neither baseline CD4+ count, nor pre-ART viral load was associated with risk of diabetes. These findings are consistent with data from prospective analyses that have failed to demonstrate associations between CD4+ nadir or baseline viremia and diabetes.[2,11] Nevertheless, more research is required to explore the relationship between immune reconstitution and insulin resistance.

Our analysis did not demonstrate any association between specific co-morbidities, tuberculosis, hypertension and malignancy, and diabetes. Data concerning co-morbidities such as dyslipidaemia, cardiovascular disease or hepatitis C co-infection that may have provided insights into the pathogenesis of DM in our setting were not collected.

No relationship between diabetes and ART adherence emerged. While there is clear evidence that psychosocial factors are important in the pathogenesis of DM in HIV-uninfected adults in southern Africa,[9] more rigorous investigation is necessary to determine the role of psychosocial determinants in both ART adherence and diabetogenesis in HIV-infected adults.

The study has several limitations. Because of the cross-sectional study design we were able only to evaluate associations between the examined variables and diabetes. Given the retrospective nature of this study, we were unable to determine whether patients had developed diabetes before or after the initiation of ART. Consequently, we could not assess whether HIV infection or ARV drug exposure played a causal role in the pathogenesis. Furthermore, despite excluding all confirmed type 1 diabetics, we could not exclude those in whom diabetes may have developed secondary to the use of drugs such as pentamidine or corticosteroids.

There were several traditional risk factors for the development of DM, such as family history, waist circumference, ethnicity, sedentary lifestyle, which were not included in our analysis. It would be valuable to assess the impact of these determinants in our setting, particularly given the increasing number of older, overweight persons living with HIV in southern Africa.[9] We were also unable to assess the potential impact of nucleoside reverse transcriptase inhibitors such as zidovudine and stavudine, both of which have been associated with an increased risk of diabetes.[2,11] Increased visceral fat and lipodystrophy, caused indirectly and directly by ARVs, may also contribute to disordered glucose homeostasis. The impact of lipodystrophy on the development of DM was not evaluated, given the retrospective nature of the study.

Conclusions

This case-control study suggests a complex interrelation among traditional host factors and treatment-related metabolic changes in the pathogenesis of DM. Patients with higher pre-ART weight and those exposed to EFV or a PI were more likely to have DM. Larger prospective studies are needed to delineate the relative contribution of other factors among people living with diabetes in southern Africa.

Acknowledgements. The Ministry of Health for granting us access to clinical data in our continued collaboration towards improving our understanding of the HIV epidemic in Botswana. This publication was made possible through assistance from the Institute of Health Sciences in Gaborone and core services and support provided by the Penn Center for AIDS Research (CFAR), a NIH-funded programme (P30 AI 045008).

References


Accepted 4 July 2013.